SKY Medical Technology: Luton and Dunstable University Hospital Have Deployed the geko Device for VTE Prevention for Acute Stroke Patients

January 6, 2021

Sky Medical Technology Ltd today announced that Luton and Dunstable University Hospital are the first NHS hospital in the South East to deploy the innovative geko device for VTE prevention in immobile acute stroke patients who cannot be prescribed the current standard of care.

Sky Medical Technology reminds us that the current standard of care for VTE prevention recommends a boot-like cuff that compresses the legs to move blood, called Intermittent Pneumatic Compression (IPC), a mechanical treatment. IPC, however, is not suitable for all patients due to vascular disease, fragile skin, reaction to the cuff materials, and patient intolerance. This results in a number of patients for whom there is currently no mechanical treatment for VTE prevention.

In an effort to address this unmet need, Luton and Dunstable University Hospital completed a clinical audit of 320 patients, prescribing the geko™ device to those patients who were not suitable for IPC treatment. The geko device is a watch-sized device that sticks to the leg to increase blood flow, via painless electrical pulses, at a rate equal to 60%[1] of walking without a patient having to move.

The audit results showed a 17% unmet need in all mechanical prophylaxis prescriptions when the geko™ device was on service and reported the need for an alternative mechanical prophylaxis intervention and the need to prescribe the geko™ as an alternative anti-stasis device (see poster).

Sky Medical Technology advises that these findings are aligned to the IPC compliance findings reported by Roffe & Natarajan[2], and the CLOTS 3 study[3]  that reports that patients immediately contraindicated to IPC and patients who become intolerant of IPC could be exposed to a VTE risk of up to 8.7%. The Luton and Dunstable Hospital enhanced pathway now offers a meaningful alternative mechanical intervention.

Dr. Lakshmanan Sekaran, Consultant Stroke Physician and Clinical Director at the Luton and Dunstable University Hospital, said: “When treating acute stroke patients, VTE is a very real and present threat to their recovery. The existing real-world data, which led us to consider the geko device, reinforced that while current methods (IPC) are effective for most patients, a small but significant number are unable to tolerate these methods, leaving them at greater risk of blood clotting.

“Recognizing the need to provide treatment for this patient group, we embraced the opportunity to examine our unmet need and determine the effectiveness of the geko™ device. The device is now in routine use across our stroke units, when IPC cannot be prescribed and ensures that all patients can now receive post-stroke VTE prevention.”

Bernard Ross, Founder, and CEO of Sky Medical Technology, the company behind the geko device, said: “The willingness of Luton and Dunstable University Hospital to embrace a safe and effective innovation is hugely significant for acute stroke patients who might otherwise fall between the cracks when it comes to blood clot prevention. Introducing any change to clinical practice requires leadership, energy, and collaboration and I applaud them.”


References:

  1. Tucker A, et al. Augmentation of venous, arterial and microvascular blood supply in the leg by isometric neuromuscular stimulation via the peroneal nerve. The International journal of angiology: official publication of the International College of Angiology, Inc. 2010 Spring;19(1): e31-7.
  2. Roffe & Natarajan et al. https://www.gekodevices.com/wp-content/uploads/2020/01/VTE-Prevention-Stroke-Royal-Stoke-Poster-1383-Patients.pdf.
  3. Dennis M, et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet. 2013; 382(9891):516-24.
  4. NICE Guidance (MTG19): https://www.nice.org.uk/guidance/mtg19/chapter/1-Recommendations
  5. Nicolaides & Griffin et al. Measurement of blood flow in the deep veins of the lower limb using the geko™ neuromuscular electro-stimulation device. Journal of International Angiology August 2016-04.
  6. NICE NG89 2018: https://www.nice.org.uk/guidance/ng89/evidence/full-guideline-volume-2-pdf-4787002770.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”